Table 1 Participant demographics by cohorts

N (%) or mean (std)

Azithromycin

(N = 101)

Placebo

(N = 97)

Single TIS + AZ

(N = 42)

Single TIS + Placebo

(N = 43)

Three TIS series + AZ

(N = 13)

Three TIS series + Placebo

(N = 10)

Age in years

6.7 (5)

6.9 (5)

6.1 (5)

7.2 (5)

8.8 (4)

7.5 (6)

Female

52 (51%)

44 (45%)

21 (50%)

21 (49%)

6 (46%)

3 (30%)

Caucasian

92 (91%)

83 (86%)

39 (93%)

38 (88%)

13 (100%)

9 (90%)

Genotype (F508del copy #)

 2

58 (57%)

49 (51%)

28 (67%)

22 (51%)

7 (54%)

5 (50%)

 1

28 (28%)

41 (42%)

8 (19%)

19 (44%)

5 (38%)

5 (50%)

 0/not done

15 (15%)

7 (7%)

6 (14%)

2 (5%)

1 (8%)

0

FEV₁% pred

N = 63

 N = 56

 N = 24

 N = 27

 N = 11

 N = 6

 < 75%

5 (8%)

7 (12%)

2 (8%)

2 (8%)

0

1 (17%)

 75-100%

31 (49%)

30 (54%)

12 (50%)

16 (59%)

6 (55%)

4 (66%)

 >= 100%

27 (43%)

19 (34%)

10 (42%)

9 (33%)

5 (45%)

1 (17%)

First lifetime PA+

60 (59%)

58 (60%)

26 (62%)

22 (51%)

7 (54%)

7 (70%)

CFTR modulator use at baseline (Ivacaftor or Ivacaftor/lumacaftor)

4 (4%)

6 (6%)

1 (2%)

3 (7%)

1 (8%)

1 (10%)

Culture result at baseline*

 P. aeruginosa

51 (51%)

41 (44%)

15 (36%)

16 (38%)

11 (85%)

6 (60%)

 S. aureus

51 (51%)

57 (61%)

22 (52%)

25 (60%)

6 (46%)

5 (50%)

 H. influenzae

8 (8%)

11 (12%)

4 (10%)

6 (14%)

2 (15%)

0

 S. maltophilia

2 (2%)

3 (3%)

1 (2%)

2 (5%)

1 (8%)

1 (10%)